丙戊酸镁联合齐拉西酮治疗双相情感障碍的效果及对血清总胆红素白蛋白炎症因子水平的影响

doi:10.3969/j.issn.1006-6233.2020.08.018

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1207 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To study clinical evaluation of magnesium valproate sustained release tablets combined with ziprasidone in treatment of bipolar disorder and effect on serum total bilirubin, albumin and inflammatory factors. Methods: 90 cases with bipolar disorder from October 2014 to October 2016 in our hospital were researched, and according to the random number table they were divided into treatment group and control group, 45 cases in each. Magnesium valproate sustained release tablet was administered to the control group, while the observation group was treated with magnesium valproate sustained release tablets combined with ziprasidone. They were compared on clinical treatment effect, serum albumin, total bilirubin and inflammatory factor levels, score of BRMS, Quality of Life and HAMD and safety. Results: After treatment, the difference between the total effective rate in treatment group (93.33%) and the total effective rate in the control group (77.78%) was statistically significant (P<0.05). The levels of serum albumin and total bilirubin in the treatment group were significantly higher than those in the control group (P<0.05), while the levels of inflammatory factors were significantly lower in the treatment group than in the control group (P<0.05). Scores of BRMS and HAMD in both groups were significantly decreased, while the life quality score was significantly increased, and the improvement of mania scale, Hamilton depression scale and life quality score in the treatment group was significantly better than that in the control group(P<0.05). Conclusion: The efficacy of magnesium valproate sustained release tablets combined with ziprasidone in the treatment of bipolar disorder was significant in reducing the score of BRMS and HAMD and improving serum total bilirubin, albumin, inflammatory factor levels, and it has less adverse reactions, being safe and reliable.

Key words： Bipolar disorder Magnesium valproate sustained-release tablets Ziprasidone Total serum bilirubin Albumin Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yan
	HE Xiance

Cite this article:

LI Yan,HE Xiance. Efficacy of Valproic Acid Combined with Ziprasidone on Bipolar Disorder and Its Effect on Serum Total Bilirubin Albumin and Inflammatory Factors[J]. HeBei Med, 2020, 26(8): 1307-1311.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.08.018 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I8/1307

[1] Fiorentino A , Sharp SI , Kandaswamy R , et al. Genetic variant analysis of the putative regulatory regions of the LRRC7 gene in bipolar disorder[J]. Psychiatric genetics, 2016, 26 (2 ):99~100.
[2] Sampath H , Sharma I , Dutta S . Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder[J]. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2016, 8(1):98~101.
[3] Vianna-Sulzbach M , Rocha NP , Teixeira AL , et al. Right hippocampus size is negatively correlated with leptin serum levels in bipolar disorder[J]. Psychiatry research, 2015, 230(2):719~721.
[4] Wessa M , Perlini C , Brambilla P . Neuropsychological underpinnings of the dynamics of bipolar disorder[J]. Epidemiology and psychiatric sciences, 2015, 24(6):479~483.
[5] McNamara RK , Jandacek R , Tso P , et al. First-episode bipolar disorder is associated with erythrocyte membrane docosahexaenoic acid deficits: Dissociation from clinical response to lithium or quetiapine[J]. Psychiatry research, 2015, 230(2):447~453.
[6] Vierck E , Porter RJ , Joyce PR . Facial recognition deficits as a potential endophenotype in bipolar disorder[J]. Psychiatry research, 2015, 230(1):102~107.
[7] Yip SW , Worhunsky PD , Rogers RD , et al. Hypoactivation of the ventral and dorsal striatum during reward and loss anticipation in antipsychotic and mood stabilizer-naive bipolar disorder[J]. Neuropsychopharmacology:official publication of the American College of Neuropsychopharmacology, 2015, 40(3):658~666.
[8] May J , Hickey M , Triantis I , et al. Spectrophotometric analysis of lithium carbonate used for bipolar disorder[J]. Biomedical optics express, 2015, 6(3):1067~1073.
[9] Kowatch R. Double TEAM: enhancing response and treating depression in patients with bipolar disorder during a mixed or manic episode[J]. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54(12):974~976.
[10] Nelson JC. Adjunctive ziprasidone in major depression and the current status of adjunctive atypical antipsychotics[J]. The American journal of psychiatry, 2015, 172(12):1176~1178.